NASDAQ:PSTX Poseida Therapeutics (PSTX) Stock Price, News & Analysis $3.37 -0.24 (-6.65%) (As of 09/20/2024 ET) Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Poseida Therapeutics alerts: Email Address About Poseida Therapeutics Stock (NASDAQ:PSTX) 30 days 90 days 365 days Advanced Chart View Price History Chart DataSkip Price History Chart Get Poseida Therapeutics alerts:Sign Up Key Stats Today's Range$3.31▼$3.6150-Day Range$2.70▼$4.0452-Week Range$1.83▼$4.27Volume954,336 shsAverage Volume568,744 shsMarket Capitalization$327.33 millionP/E RatioN/ADividend YieldN/APrice Target$14.67Consensus RatingBuy Company OverviewPoseida Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing therapeutics for patients with high unmet medical needs. The company's development candidates for Heme Malignancies includes P-BCMA-ALLO1, which is in Phase I trial to treat patients with relapsed/refractory multiple myeloma; P-CD19CD20-ALLO1, which is in Phase I trial for treating B cell malignancies and other autoimmune diseases; P-BCMACD19-ALLO1, an allogeneic, off-the-shelf CAR-T product candidate in preclinical development for treating multiple myeloma; and P-CD70-ALLO1 under preclinical development to treat hematological indications. It is also involved in the development of P-MUC1C-ALLO1 that is in Phase I trial for treating a range of solid tumors, including breast, colorectal, lung, ovarian, pancreatic, and renal cancers; P-PSMA-ALLO1, an autologous chimeric antigen receptor T cell (CAR-T) product candidate that is in preclinical development for the treatment of patients with metastatic castrate resistant prostate cancer (mCRPC); and P-PSMA-101, an allogeneic CAR-T product candidate under Phase 1 clinical trial for treating mCRPC. In addition, the company engages in the development of P-FVIII-101, a clinical stage liver-directed gene therapy for the in vivo treatment of hemophilia A; P-OTC-101, a clinical stage liver-directed gene therapy for the in vivo treatment of ornithine transcarbamylase deficiency; and P-PAH-101, a clinical stage liver-directed gene therapy for the in vivo treatment of phenylketonuria. It has a research collaboration and license agreement with F. Hoffmann-La Roche Ltd, and Hoffmann-La Roche Inc. The company was incorporated in 2014 and is headquartered in San Diego, California.Read More… Forget Trump and Kamala (Ad)Forget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.Download my Dividend Calendar here Poseida Therapeutics Stock Analysis - MarketRank™See Top Rated MarketRank™ StocksOverall MarketRank™: 76th PercentilePoseida Therapeutics scored higher than 76% of companies evaluated by MarketBeat, and ranked 268th out of 1,007 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.5 / 5Analyst RatingBuy Consensus RatingPoseida Therapeutics has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 3 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoveragePoseida Therapeutics has only been the subject of 1 research reports in the past 90 days.Read more about Poseida Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Poseida Therapeutics are expected to decrease in the coming year, from ($1.57) to ($1.97) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Poseida Therapeutics is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Poseida Therapeutics is -2.92, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioPoseida Therapeutics has a P/B Ratio of 3.21. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Poseida Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.02% of the outstanding shares of Poseida Therapeutics have been sold short.Short Interest Ratio / Days to CoverPoseida Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Poseida Therapeutics has recently increased by 6.27%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldPoseida Therapeutics does not currently pay a dividend.Dividend GrowthPoseida Therapeutics does not have a long track record of dividend growth. Sustainability and ESG4.6 / 5Environmental Score-0.93 Percentage of Shares Shorted4.02% of the outstanding shares of Poseida Therapeutics have been sold short.Short Interest Ratio / Days to CoverPoseida Therapeutics has a short interest ratio ("days to cover") of 9.3.Change versus previous monthShort interest in Poseida Therapeutics has recently increased by 6.27%, indicating that investor sentiment is decreasing significantly. News and Social Media1.8 / 5News Sentiment0.15 News SentimentPoseida Therapeutics has a news sentiment score of 0.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.46 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 2 news articles for Poseida Therapeutics this week, compared to 2 articles on an average week.Search Interest5 people have searched for PSTX on MarketBeat in the last 30 days. This is an increase of 25% compared to the previous 30 days.MarketBeat FollowsOnly 2 people have added Poseida Therapeutics to their MarketBeat watchlist in the last 30 days. This is a decrease of -75% compared to the previous 30 days. Company Ownership0.8 / 5Insider TradingN/A Insider Buying vs. Insider SellingIn the past three months, Poseida Therapeutics insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 2.90% of the stock of Poseida Therapeutics is held by insiders.Percentage Held by Institutions46.87% of the stock of Poseida Therapeutics is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Poseida Therapeutics' insider trading history. Receive PSTX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Poseida Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Email Address PSTX Stock News HeadlinesFDA grants RMAT to Poseida’s CAR-T cell therapy P-BCMA-ALLO1September 17 at 11:49 PM | msn.comPoseida Therapeutics Receives Regenerative Medicine Advanced Therapy (RMAT) Designation from FDA for P-BCMA-ALLO1 to Treat Relapsed/Refractory Multiple MyelomaSeptember 16, 2024 | prnewswire.comForget Trump and KamalaForget Trump and Kamala. I don't care who you vote for - This calendar is the only thing that matters right now.September 20, 2024 | Investors Alley (Ad)Poseida Therapeutics: An Underappreciated Company Continuing To Shape Up Well In 2024September 9, 2024 | seekingalpha.comPoseida Therapeutics to Present New Clinical Data from Phase 1 Study of Allogeneic CAR-T P-BCMA-ALLO1 in Patients with Relapsed/Refractory Multiple Myeloma at 21st International Myeloma Society Annual MeetingSeptember 5, 2024 | prnewswire.comPoseida Therapeutics Presents New Case Study Demonstrating Reactivation of CAR-T Therapy with a T-Cell Engager in a Patient with Relapsed Multiple MyelomaSeptember 4, 2024 | prnewswire.comPoseida Therapeutics to Present at Upcoming Investor ConferencesAugust 29, 2024 | prnewswire.comBuy Rating for Poseida Therapeutics: Strategic Partnerships and Innovative Cell Therapy PlatformAugust 13, 2024 | markets.businessinsider.comSee More Headlines PSTX Stock Analysis - Frequently Asked Questions How have PSTX shares performed this year? Poseida Therapeutics' stock was trading at $3.36 at the beginning of the year. Since then, PSTX shares have increased by 3.3% and is now trading at $3.47. View the best growth stocks for 2024 here. How were Poseida Therapeutics' earnings last quarter? Poseida Therapeutics, Inc. (NASDAQ:PSTX) posted its quarterly earnings results on Monday, August, 5th. The company reported ($0.32) EPS for the quarter, beating the consensus estimate of ($0.43) by $0.11. The firm had revenue of $25.97 million for the quarter, compared to the consensus estimate of $13.75 million. Poseida Therapeutics had a negative trailing twelve-month return on equity of 121.01% and a negative net margin of 127.48%. When did Poseida Therapeutics IPO? Poseida Therapeutics (PSTX) raised $150 million in an initial public offering on Friday, July 10th 2020. The company issued 10,000,000 shares at $14.00-$16.00 per share. BofA Securities, Piper Sandler and William Blair acted as the underwriters for the IPO. Who are Poseida Therapeutics' major shareholders? Top institutional investors of Poseida Therapeutics include Blair William & Co. IL (1.14%), Renaissance Technologies LLC (0.88%), Dimensional Fund Advisors LP (0.62%) and Acadian Asset Management LLC (0.41%). Insiders that own company stock include Life Sciences Holdings L Malin, Eric Ostertag and Kerry D Ingalls. View institutional ownership trends. How do I buy shares of Poseida Therapeutics? Shares of PSTX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Poseida Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Poseida Therapeutics investors own include Moderna (MRNA), Advanced Micro Devices (AMD), AngloGold Ashanti (AU), Micron Technology (MU), Eaton (ETN), Corning (GLW) and OPKO Health (OPK). Company Calendar Last Earnings8/05/2024Today9/20/2024Next Earnings (Estimated)11/14/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biological products, except diagnostic Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:PSTX CUSIPN/A CIK1661460 Webwww.poseida.com Phone858-779-3100FaxN/AEmployees260Year FoundedN/APrice Target and Rating Average Stock Price Target$14.67 High Stock Price Target$20.00 Low Stock Price Target$10.00 Potential Upside/Downside+306.3%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage3 Analysts Profitability EPS (Most Recent Fiscal Year)($1.19) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-123,430,000.00 Net Margins-127.48% Pretax Margin-127.36% Return on Equity-121.01% Return on Assets-39.66% Debt Debt-to-Equity Ratio0.97 Current Ratio2.48 Quick Ratio2.48 Sales & Book Value Annual Sales$88.46 million Price / Sales3.96 Cash FlowN/A Price / Cash FlowN/A Book Value$1.08 per share Price / Book3.34Miscellaneous Outstanding Shares96,958,000Free Float94,146,000Market Cap$350.02 million OptionableOptionable Beta0.51 5G Stocks: The Path Forward is ProfitableClick the link below and we'll send you MarketBeat's guide to investing in 5G and which 5G stocks show the most promise. Get This Free Report This page (NASDAQ:PSTX) was last updated on 9/20/2024 by MarketBeat.com Staff From Our PartnersTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredTrump’s “Tax Free” Retirement StrategySince 1924 — over one hundred years — the US dollar has lost nearly 18x its value. If you're planning on re...Gold Safe Exchange | SponsoredThe election trade you can't losePolitics is an unpredictable game. But no matter what happens in the next few months... There's one thin...Investors Alley | SponsoredAre You Ready for a Small-Cap Rally?Jeff Bezos has just made a bold move into Quantum Computing as a Service (QaaS), a technology set to disrupt i...InvestorPlace | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredMust-Know for Trading OptionsOptions are becoming increasingly popular among investors – with demand hitting record highs for 3 years in a ...Unstoppable Prosperity | SponsoredMan who Predicted Trump 2016 Win: “Prepare for Election Meltdown”Former advisor to the CIA, the Pentagon and the White House Jim Rickards went on multiple TV news programs… ...Paradigm Press | SponsoredUnlock the Secret to Easy Wins with Iron CondorsDiscover the power of Iron Condor trades – a low-risk, high-reward strategy that allows you to profit consiste...Netpicks | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Poseida Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Poseida Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.